Ministry of Health and Welfare weighing public price comparisons as out-of-pocket costs likely at launch; WHO guidance on 12-week limit expected to fuel debate over Korea's 9-week cap; parental consent for minors and hospitalization requirements among key issues still to be resolved
With the government having confirmed it will introduce the oral abortion drug mifepristone for women up to nine weeks pregnant starting in the first quarter of next year, attention is turning to questions of cost, national health insurance coverage, prescription procedures and consent standards for minors — all of which remain unresolved.
The Ministry of Health and Welfare said it will review drug pricing and insurance eligibility once a pharmaceutical company completes product approval from the Ministry of Food and Drug Safety and applies for coverage. The drug is widely expected to be offered on a non-covered, out-of-pocket basis when it first becomes available.
If dispensed without insurance coverage, patients would bear the full cost of not only the medication but also consultations and diagnostic tests. The process goes beyond simply taking a pill: before administration, clinicians must confirm gestational age and rule out ectopic pregnancy, and follow-up visits are required afterward to verify that the termination is complete.
The debate over national health insurance coverage is therefore expected to extend well beyond whether the drug itself should be reimbursed. What range of services qualifies — pre-administration tests such as ultrasounds, post-administration confirmation visits, and treatment for complications such as bleeding or infection — will all be contested.
Out-of-pocket costs also present a variable. Without insurance coverage, prices could vary by clinic, and if the market initially sets fees high, access for lower-income patients could suffer. The government is considering publishing price comparisons across medical institutions through the Health Insurance Review and Assessment Service to reduce such disparities.
Debate over the permitted gestational limit is also expected to continue after the drug's introduction.
The government capped eligibility at nine weeks on the grounds that the pharmaceutical company conducted clinical trials on patients within that window to establish safety. Yet WHO and other international health bodies describe medication abortion under medical supervision as "safe and effective" through 12 weeks of pregnancy.
Major countries including the United Kingdom and the United States allow medication abortion up to 10 to 12 weeks under their respective guidelines. Women's groups and parts of the medical community are expected to keep pressing for the domestic limit to be raised in line with global standards after the drug's introduction.
Opponents counter, however, that the risk of incomplete abortion and heavy bleeding rises with gestational age, and argue that the nine-week limit should be strictly maintained.
Clinical guidelines that the medical community will develop are expected to include a parental — or legal guardian — consent requirement for minors, a provision likely to ignite fresh controversy over how effectively it protects adolescents.
The current Mother and Child Health Act defines consent for abortion procedures as resting solely with the patient and her spouse, leaving a fundamental gap in protecting the reproductive rights and health of underage adolescents.
If parental consent is made mandatory, teenagers who cannot obtain it — due to family conflict, neglect or abuse — may avoid medical facilities altogether and instead seek counterfeit or illegally copied drugs through unofficial channels, with potentially serious consequences.
To bring such individuals safely within the formal healthcare system, discussions are needed on detailed safeguards such as designating counseling agencies that could substitute for parental consent, or establishing exemption clauses from the legal guardian requirement.
Whether patients must be hospitalized during administration, and the specific protocol for taking the medication, are also central issues for the medical community's guidelines.
The regimen typically involves two drugs — mifepristone and misoprostol — taken in sequence with a gap of one to two days. Uterine contractions begin shortly after the second drug is taken and can cause severe abdominal pain, vomiting and heavy bleeding, requiring close medical monitoring. Authorities will need to establish whether patients must remain in hospital or on-site after taking the medication, or whether at-home waiting — as is common abroad — will be permitted.
The medical community is calling for concrete guidelines, such as mandatory on-site waiting or short-term hospitalization, to ensure patient safety, while also seeking legal protections for physicians — including liability exemptions or legislative safeguards — in the event of medical complications.
thlee@heraldcorp.com
